STOCK TITAN

Palatin Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Palatin Technologies (PTN) reported a fiscal first-quarter 2027 net loss of $5,057,511 while advancing its experimental obesity drug programs. Revenue for the quarter ended September 30, 2026 fell to $361,802 from $8,847,550 a year earlier, when revenue included upfront and milestone payments. The prior-year quarter generated net income of $4,677,534. Cash declined to $3,740,424 from $7,492,014 at June 30, 2026. Additional funding is required, and substantial doubt exists about continued operations for one year following issuance of the financial statements.

Palatin targets a first human study of its long-acting MC4R peptide in the first half of 2027, with initial data in the second half. Its oral small-molecule study is targeted for the second half of 2027, with initial data in the first half of 2028. Studies needed before human testing and manufacturing activities are ongoing for the peptide.

Loading...
Loading translation...
11 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 11 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Boehringer Ingelheim collaboration reimburses approved research costs and provides potential milestones and tiered royalties if products commercialize.
  • Moderate pointPL9643 sublicense assigns future development and commercialization to Altanispac; Palatin remains eligible for additional payments and tiered royalties.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Long-acting peptide Phase 1 initiation targeted for first-half 2027; initial data targeted for second-half 2027.
  • Minor pointPL2000 peptide reduced food intake and body weight with once-weekly injections in an obese mouse model.
  • Minor pointTested peptide compounds activated MC4R without MC1R agonism, supporting Palatin's goal of reducing treatment-related skin darkening.
6 minor points
  • Minor pointPL1000 development continues, including controlled-release formulations as another approach to long-acting therapy.
  • Minor pointOral small-molecule candidates showed improved potency and MC4R selectivity versus earlier compounds in preclinical studies.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Oral program targets pre-human-testing development in first-half 2027 and Phase 1 initiation in second-half 2027.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Oral small-molecule initial clinical data targeted for the first half of 2028.
  • Minor pointOral peptide agonist approach is also being explored to expand the development portfolio.
  • Minor pointPartnering opportunities remain under evaluation for bremelanotide in obesity, ulcerative colitis assets and the diabetic nephropathy program.

Negative

  • Major pointAdditional funding is required; substantial going-concern doubt covers one year following issuance of the financial statements.
  • Major pointNet result shifted to a $5,057,511 loss from $4,677,534 income in the prior-year quarter.
  • Moderate pointQuarterly revenue fell to $361,802 from $8,847,550; the prior-year period included upfront and milestone revenue.
  • Moderate pointOperating cash use increased to approximately $3.7 million from approximately $1.6 million in the prior-year quarter.
  • Moderate pointCash and equivalents declined to $3,740,424 at September 30, 2026, from $7,492,014 at June 30, 2026.
  • Moderate pointR&D expense rose to $3,383,743 from $2,525,766; MC4R obesity spending increased to approximately $2.1 million from approximately $1.0 million.
  • Moderate pointWorking capital declined to $1,780,825 at September 30, 2026, from $6,392,514 at June 30, 2026.
4 minor points
  • Minor pointBasic/diluted loss per share was $1.29, versus prior-year basic/diluted earnings of $4.81/$4.26.
  • Minor pointGeneral and administrative expense rose to $2,080,414 from $1,660,731, reflecting higher stock-based compensation and professional fees.
  • Minor pointStockholders' equity declined to $2,026,079 at September 30, 2026, from $6,686,465 at June 30, 2026.
  • Minor pointTotal liabilities increased to $2,692,098 at September 30, 2026, from $1,837,389 at June 30, 2026.

News Explained

Palatin said additional funding is required; its cash balance at September 30, 2026, of $3,740,424 equals 92 days of the last reported quarterly operating cash use of $3,741,589, at that quarter’s rate.

Sources and calculations
  • Available liquidity against the last reported quarterly operating outflow, in days at that rate $3,740,424 / ($3,741,589 / 92) = 92 days

Key Figures

Collaboration and license revenue: Approximately $0.4 million vs. approximately $8.8 million MC4R obesity program R&D: Approximately $2.1 million vs. approximately $1.0 million Net loss: Approximately $5.1 million +5 more
Collaboration and license revenue
Approximately $0.4 million vs. approximately $8.8 million
Fiscal Q1 2027 vs. comparable prior-year period
MC4R obesity program R&D
Approximately $2.1 million vs. approximately $1.0 million
Fiscal Q1 2027 vs. comparable prior-year period
Net loss
Approximately $5.1 million
Fiscal Q1 2027
Net cash used in operating activities
Approximately $3.7 million vs. approximately $1.6 million
Fiscal Q1 2027 vs. comparable prior-year period
Cash and cash equivalents
Approximately $3.7 million vs. approximately $7.5 million
September 30, 2026 vs. June 30, 2026
Going-concern assessment
One year following issuance of the financial statements
Substantial doubt stated about the company’s ability to continue as a going concern
Long-acting peptide Phase 1
Initiation targeted for the first half of calendar 2027; initial data targeted for the second half of 2027
MC4R-selective peptide program
Oral small-molecule Phase 1
Initiation targeted for the second half of calendar 2027; initial data targeted for the first half of 2028
MC4R-selective oral program

Previous Earnings Reports

1 past event · Latest: Sep 28
Same Type 1 event
  1. Sep 28

    Fiscal-year results

    24h Move
    -5.1%

    Reported $7.5 million cash and said additional financing was needed to support development.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

mc4r, mc1r, pharmacokinetic, ind-enabling, +1 more
5 terms
mc4r medical
"next-generation MC4R-selective obesity development programs"
mc4r is a gene that makes a protein in the brain acting like a thermostat for appetite and energy use; when it works normally it helps signal when to eat and when to stop. It matters to investors because changes in this gene or drugs that target its protein can alter obesity and metabolic disease outcomes, influencing clinical trial results, regulatory approvals, and the commercial prospects of therapies.
mc1r medical
"minimal to no MC1R activity in tested peptide compounds"
MC1R is a human gene that encodes a protein on cell surfaces involved in skin and hair pigmentation and in cellular responses to ultraviolet light. For investors, changes or mutations in MC1R matter because they can influence disease risk (notably certain skin cancers), be used as biomarkers, or serve as targets for diagnostics and therapies—think of it as a control switch that drug developers or diagnostic companies might aim to measure or modify.
pharmacokinetic medical
"Preclinical pharmacokinetic findings support the potential"
Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.
ind-enabling regulatory
"IND-enabling studies and chemistry, manufacturing and controls"
Ind-enabling describes the preclinical tests and safety work a drug candidate must pass before a company can ask regulators for permission to start human trials (an Investigational New Drug or IND filing). Think of it as the mechanical inspection and crash-testing a prototype car needs before it can legally be driven on public roads; for investors, successful ind-enabling work reduces technical and regulatory risk and makes clinical progress and potential value creation more likely.
cmc technical
"chemistry, manufacturing and controls ("CMC") activities are ongoing"
Chemistry, Manufacturing, and Controls (CMC) describes the technical documentation and processes that show how a drug or medical product is made, tested for consistent quality, and kept stable from batch to batch. Investors care because strong CMC means a product can be manufactured reliably at scale and meet regulatory standards—similar to proving a recipe can be cooked the same way in any kitchen before restaurants expand—affecting approval, production costs, and potential revenue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Advancing differentiated next-generation MC4R agonists toward first-in-human clinical studies in 2027

  • Lead lipidated, long-acting MC4R-selective peptide advancing through IND-enabling and manufacturing activities, with Phase 1 initiation targeted for the first half of calendar 2027
  • Preclinical findings demonstrate selective and potent MC4R agonism with minimal to no MC1R activity in tested peptide compounds, supporting the potential to substantially reduce or eliminate MC1R-mediated hyperpigmentation
  • Expanding oral MC4R opportunities through next-generation small-molecule development and an oral peptide agonist approach
  • Oral small-molecule MC4R-selective agonist Phase 1 study targeted for the second half of calendar 2027
  • First-quarter R&D investment in MC4R obesity programs more than doubled year over year, reflecting advancement of key preclinical development activities
  • Conference call and webcast scheduled for November 17, 2026 at 11:00 a.m. ET

PRINCETON, N.J., Nov. 17, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (Nasdaq: PTN), a biopharmaceutical company developing medicines targeting the melanocortin receptor ("MCR") system, today announced financial results for its fiscal 2027 first quarter ended September 30, 2026, and provided an update on its next-generation MC4R-selective obesity development programs and strategic partnerships.

Palatin Technologies, Inc.

"MC4R agonism is now a clinically and commercially validated therapeutic approach for rare neuroendocrine obesity disorders, and we believe the next generation of therapies will be defined not only by efficacy, but by meaningful improvements in tolerability, convenience and long-term usability," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies. "Our development strategy is specifically designed to address these challenges. We are building on more than two decades of melanocortin research and drug development experience to advance highly selective MC4R agonists with the potential to deliver robust efficacy while substantially reducing, and potentially eliminating, MC1R-mediated hyperpigmentation."

"Our lead lipidated peptide program represents a particularly compelling opportunity," continued Dr. Spana. "We have demonstrated significant efficacy with once-weekly dosing in preclinical models, and pharmacokinetic findings support the potential for once-weekly or less frequent administration in humans. Equally important, tested compounds in our next-generation peptide series have demonstrated potent MC4R activation without meaningful MC1R activation, an important attribute for developing therapies with improved long-term tolerability. We believe this combination of selectivity, efficacy and sustained activity provides a strong foundation for developing a differentiated therapy for patients who require lifelong treatment."

"During the quarter, we continued to advance IND-enabling activities with our long-acting peptide while progressing our next-generation oral small-molecule candidates and additionally exploring oral peptide opportunities. We are targeting the initiation of our first Phase 1 study in the first half of 2027, followed by our oral small-molecule program in the second half of 2027. We believe these programs have the potential to establish a new standard for MC4R-targeted treatment of rare obesity disorders."

MC4R Obesity Program Update

Palatin is advancing a portfolio of MC4R-selective agonists designed to address hypothalamic obesity ("HO"), Prader-Willi syndrome ("PWS"), Bardet-Biedl syndrome ("BBS") and other rare obesity disorders associated with dysfunction of the melanocortin pathway.

The Company's strategy focuses on developing therapies with meaningful efficacy, improved gastrointestinal tolerability, reduced or eliminated MC1R-mediated hyperpigmentation, and dosing characteristics suitable for chronic treatment.

Next-Generation Long-Acting Peptide MC4R Agonists

Palatin is advancing two complementary MC4R-selective peptide series: lipidated PL2000 and non-lipidated PL1000.

  • The lead lipidated PL2000 development candidate has demonstrated significant reductions in food intake and body weight following once-weekly subcutaneous administration in a diet-induced obese mouse model.
  • Preclinical pharmacokinetic findings support the potential for once-weekly or less frequent dosing in humans.
  • Tested compounds from both peptide series have demonstrated potent MC4R agonist activity without acting as agonists at MC1R, supporting the Company's objective of substantially reducing or potentially eliminating hyperpigmentation associated with MC1R activation.
  • IND-enabling studies and chemistry, manufacturing and controls ("CMC") activities are ongoing for the lead lipidated peptide candidate.
  • Palatin is targeting initiation of a Phase 1 single-ascending-dose/multiple-ascending-dose ("SAD/MAD") clinical study in the first half of calendar 2027, with initial data targeted in the second half of 2027.
  • The Company continues to advance its non-lipidated PL1000 peptide series, including controlled-release formulation development, as an additional approach to long-acting MC4R therapy.

Next-Generation Oral MC4R Agonists

Palatin is pursuing oral MC4R-selective therapies through its small-molecule development program and an additional oral peptide agonist approach.

The oral small-molecule program incorporates data and learnings from earlier development candidates, including PL7737, together with advanced medicinal chemistry, computational drug design, artificial intelligence and machine learning capabilities.

  • Preclinical studies have identified next-generation oral small-molecule candidates with improved potency and MC4R selectivity relative to earlier compounds, together with favorable oral bioavailability.
  • The program is designed to achieve meaningful efficacy with improved tolerability and minimal or no MC1R-mediated hyperpigmentation.
  • Lead candidate selection and optimization activities are ongoing, with IND-enabling development targeted for the first half of calendar 2027.
  • A Phase 1 SAD/MAD study is targeted to initiate in the second half of calendar 2027, with initial clinical data targeted in the first half of 2028.
  • Palatin is also exploring an oral peptide agonist approach as an additional opportunity to expand its MC4R-selective therapeutic portfolio.

Partnering and Out-Licensing Programs

Retinal Diseases – Boehringer Ingelheim

Palatin continues to collaborate with Boehringer Ingelheim on proprietary melanocortin receptor-targeted compounds for retinal diseases, including diabetic retinopathy and diabetic macular edema. Palatin provides research and development support, with approved costs reimbursed by Boehringer Ingelheim.

The agreement provides for potential future development, regulatory and commercial milestone payments, as well as tiered royalties on net sales of licensed products, if commercialized.

Palatin recognized approximately $0.4 million in revenue related to the collaboration during the fiscal first quarter.

PL9643 – Dry Eye Disease

Palatin's exclusive sublicense agreement with Altanispac Labs covers PL9643 for the treatment of dry eye disease. Altanispac is responsible for future development and commercialization. Palatin remains eligible for additional payments and tiered royalties under the agreement.

Additional Development and Partnering Opportunities

Palatin continues to evaluate strategic partnering and out-licensing opportunities for its bremelanotide co-administration program in obesity, PL8177 or other novel MC1R agonist in ulcerative colitis and its melanocortin receptor agonist program for diabetic nephropathy.

These programs provide opportunities to advance additional assets through strategic collaborations while maintaining Palatin's primary development focus on next-generation MC4R therapies for rare obesity disorders.

Fiscal 2027 First Quarter Ended September 30, 2026 Financial Results Revenue

For the fiscal first quarter ended September 30, 2026, Palatin recognized approximately $0.4 million in collaboration and license revenue, compared with approximately $8.8 million for the comparable prior-year period.

Revenue for the current quarter was attributable to research and development services performed under the Boehringer Ingelheim collaboration. The prior-year period included upfront and milestone revenue associated with that agreement.

Research and Development Expenses

Research and development expenses were approximately $3.4 million, compared with approximately $2.5 million for the comparable prior-year period.

R&D spending directly related to the Company's MC4R obesity programs increased to approximately $2.1 million from approximately $1.0 million in the prior-year period. The increase was primarily attributable to IND-enabling preclinical studies and related activities for the long-acting MC4R peptide program and lead candidate optimization activities for the oral small-molecule program.

General and Administrative Expenses

General and administrative expenses were approximately $2.1 million, compared with approximately $1.7 million for the comparable prior-year period. The increase was primarily attributable to higher stock-based compensation expenses and professional fees.

Net Loss

Palatin reported a net loss of approximately $5.1 million, or $1.29 per basic and diluted common share, for the fiscal first quarter ended September 30, 2026.

Cash Flows and Cash Position

Net cash used in operating activities was approximately $3.7 million for the fiscal first quarter ended September 30, 2026, compared with approximately $1.6 million for the comparable prior-year period.

As of September 30, 2026, Palatin had cash and cash equivalents of approximately $3.7 million, compared with approximately $7.5 million as of June 30, 2026.

The Company intends to pursue additional financing and strategic opportunities to support continued advancement of its development programs. Additional funding will be required to execute its planned development activities and fund operations. Accordingly, substantial doubt exists regarding the Company's ability to continue as a going concern for one year following issuance of its financial statements.

Conference Call and Webcast

Palatin will host a conference call and audio webcast on November 17, 2026, at 11:00 a.m. Eastern Time, to discuss its fiscal first-quarter financial results and provide an update on corporate and development activities.

To listen to the live conference call, dial 1-888-506-0062 (US) or 1-973-528-0011 (International), Participant Access Code: 336522. The audio webcast and replay can be accessed by logging on to the "Investor-Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and audio webcast replay will be available one hour after the completion of the call. To access the telephone replay, dial 1-877-481-4010 (US) or 1-919-882-2331 (International), Replay Passcode 54837. The webcast and telephone replay will be available through December 1, 2026.

About Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company developing medicines targeting the melanocortin receptor system. Palatin's principal strategic development focus is advancing next-generation MC4R-selective agonists for rare neuroendocrine obesity disorders, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. The Company is developing long-acting injectable peptide agonists, oral small-molecule agonists and an oral peptide agonist approach, with the objective of delivering differentiated efficacy, tolerability and dosing profiles suitable for long-term treatment. Palatin also utilizes collaborations, licensing arrangements and strategic partnerships to advance other melanocortin-based programs. For more information, visit www.palatin.com.

Forward-Looking Statements

Statements in this press release that are not historical facts, including statements regarding Palatin's product candidates, potential clinical benefits, efficacy, tolerability, receptor selectivity, dosing frequency, development programs, regulatory submissions, clinical trial initiation and results, collaborations, financing plans and future operations, are forward-looking statements within the meaning of applicable federal securities laws. These statements involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include the results of preclinical and clinical studies, regulatory decisions, manufacturing and development timelines, Palatin's ability to obtain sufficient financing, the performance of collaborators and licensees, competing therapies, market conditions and other risks described in Palatin's filings with the Securities and Exchange Commission. Palatin undertakes no obligation to update forward-looking statements except as required by law.


PALATIN TECHNOLOGIES, INC


and Subsidiary


Consolidated Statements of Operations


(unaudited)









Three Months Ended September 30,




2026


2025









REVENUES






Collaboration and license

$                    361,802


$                8,847,550









OPERATING EXPENSES






Research and development

3,383,743


2,525,766



General and administrative

2,080,414


1,660,731



Total operating expenses

5,464,157


4,186,497









(Loss) Income from operations

(5,102,355)


4,661,053









OTHER INCOME (EXPENSE)






Investment income

46,534


18,483



Interest expense

(1,690)


(2,002)



Total other (expense) income, net

44,844


16,481









NET (LOSS) INCOME

$               (5,057,511)


$                4,677,534









Basic net (loss) income per common share

$                        (1.29)


$                         4.81









Diluted net (loss) income per common share

$                        (1.29)


$                         4.26









Weighted average number of common shares
outstanding used in computing basic net (loss)
income per common share

3,922,464


971,650









Weighted average number of common shares
outstanding used in computing diluted net (loss)
income per common share

3,922,464


1,098,490


 


PALATIN TECHNOLOGIES, INC


and Subsidiary


Consolidated Balance Sheets


(unaudited)








September 30, 2026


June 30, 2026


ASSETS





Current assets:





Cash and cash equivalents

$                  3,740,424


$      7,492,014


Accounts receivable

361,802


300,770


Prepaid expenses and other current assets

337,765


371,703


Total current assets

4,439,991


8,164,487







Property and equipment, net

101,112


118,064


Right-of-use assets - operating leases

155,448


219,677


Other assets

21,626


21,626


Total assets

$                  4,718,177


$      8,523,854







LIABILITIES AND STOCKHOLDERS' EQUITY





Current liabilities:





Accounts payable

$                  1,360,530


$      1,109,552


Accrued expenses

1,171,975


504,158


Short-term operating lease liabilities

126,661


158,263


Total current liabilities

2,659,166


1,771,973







Long-term operating lease liabilities

32,932


65,416


Total liabilities

2,692,098


1,837,389







Stockholders' equity:





Preferred stock of $0.01 par value – authorized 10,000,000 shares: shares





issued and outstanding designated as follows:





Series A Convertible: authorized 4,030 shares as of September 30, 2026: issued





and outstanding 4,030 shares as of September 30, 2026 and June 30, 2026

40


40


Series D Convertible: authorized 3,400 shares as of September 30, 2026: issued





and outstanding 3,400 shares as of September 30, 2026 and June 30, 2026

34


34


Common stock of $0.01 par value – authorized 300,000,000 shares:





issued and outstanding 1,780,939 shares as of September 30, 2026 and 1,779,275
shares as of June 30, 2026

17,809


17,793


Additional paid-in capital

474,517,501


474,120,392


Accumulated deficit

(472,509,305)


(467,451,794)


Total stockholders' equity

2,026,079


6,686,465


Total liabilities and stockholders' equity

$                  4,718,177


$      8,523,854

















BS Check

$                                -


$                   -


Working Capital

1,780,825


6,392,514

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-reports-fiscal-first-quarter-2027-financial-results-and-provides-business-update-302941645.html

SOURCE Palatin Technologies, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Palatin's fiscal first-quarter 2027 financial results?

Palatin reported $361,802 in revenue and a $5,057,511 net loss for the quarter ended September 30, 2026. The comparable prior-year quarter had revenue of $8,847,550 and net income of $4,677,534. Basic and diluted loss per share was $1.29.

When does Palatin expect to begin human trials of its MC4R obesity drugs?

Palatin targets first-half 2027 initiation for its long-acting peptide Phase 1 study and second-half 2027 initiation for its oral small-molecule Phase 1 study. Initial peptide data are targeted for the second half of 2027, followed by initial oral small-molecule data in the first half of 2028.

What does Palatin's Boehringer Ingelheim collaboration cover?

The collaboration covers melanocortin receptor-targeted compounds for retinal diseases, including diabetic retinopathy and diabetic macular edema. Palatin provides research and development support, with approved costs reimbursed by Boehringer Ingelheim. The agreement also provides potential development, regulatory and commercial milestones, plus tiered royalties on net sales if licensed products are commercialized.

Who is responsible for developing Palatin's PL9643 dry eye treatment?

Altanispac Labs is responsible for future development and commercialization of PL9643 under its exclusive sublicense agreement with Palatin. Palatin remains eligible for additional payments and tiered royalties under the agreement.

Keep reading